A phase II randomized trial of adjuvant chemotherapy for the patients completely resected pathological stage IB(T>5cm), II, IIIA Non Small Cell Lung Cancer comparing S-1 / S-1 with CDDP
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-UMIN000001765
- Lead Sponsor
- Kyushu University,Graduate School of Medical Science,Department of Surgery and Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 140
Not provided
(1)A history of severe allergic reactions to drugs (2)Patients who have already received CDDP,S-1 (3)myocardial infarction within 6 months (4)apparent interstitial pneumonitis or pulmonary fibrosis (5)Patients with an unstable or serious heart disease (6)Patients with an unstable or serious psychic disease (7)uncontrolled diabetes mellitus (8)Patients with Paralysis of intestine or ileus (9)Patients with an active infection (10)Patients with other severe complication (11)The presence of other concomitant or metachronous cancers (12)Pregnant or expecting or lactating woman (13)Male patient who intends to make someone pregnant during this study (14)Patient who requires continuous use of flucytosine , phenytoin or warfarin potassium (15)systemic steroid therapy required (16)Patient who is judged to be inappropriate as subject to this study by the principal investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year desease free survival rate
- Secondary Outcome Measures
Name Time Method overall survival,desease free survival,safety,feasibility(dose intensity included)